Nabla Bio Secures $26M Series A Financing and Collaborations with AstraZeneca, Bristol Myers Squibb and Takeda for Generative Protein Design
➢ Company builds integrated AI and wet lab technologies to design developable, selective, and functionally active protein drugs against multipass membrane protein targets ➢ Radical Ventures leads new investment in Nabla Bio as company secures strategic pharmaceutical…